ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen

PHASE3UnknownINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

May 31, 1997

Primary Completion Date

February 29, 2008

Conditions
Malignant Mesothelioma
Interventions
DRUG

doxorubicin hydrochloride

Given IV

DRUG

ranpirnase

Given IV

Trial Locations (19)

16132

Istituto Nazionale per la Ricerca sul Cancro, Genoa

Ospedale San Martino, Genoa

21201

Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore

27100

Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia

46601

CCOP - Northern Indiana CR Consortium, South Bend

49503

Spectrum Health Hospital - Butterworth Campus, Grand Rapids

63301

Missouri Cancer Care, PC at St. Joseph Health Center - St. Charles, Saint Charles

55805-1983

CCOP - Duluth, Duluth

68114-4199

Methodist Estabrook Cancer Center, Omaha

87131-5636

University of New Mexico Cancer Research and Treatment Center, Albuquerque

D-82131

Asklepios Fachkliniken Muenchen-Gauting, Gauting

D-22927

Hospital Grosshansdorf, Großhansdorf

D-20099

Asklepios Klinik St. Georg, Hamburg

D-21075

Asklepios Klinik Harburg, Hamburg

D-81675

Klinikum Rechts Der Isar - Technische Universitaet Muenchen, Munich

80-211

Medical University of Gdansk, Gdansk

PL-60 569

University School of Medical Sciences, Poznan

02-781

Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw

41-803

Klinika Chrorob Pluc I Gruzlicy, Zabrze

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Alfacell

INDUSTRY

NCT00003034 - ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen | Biotech Hunter | Biotech Hunter